<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39356775</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-960X</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of chemical information and modeling</Title><ISOAbbreviation>J Chem Inf Model</ISOAbbreviation></Journal><ArticleTitle>Evaluation of an Affinity-Enhanced Anti-SARS-CoV2 Nanobody Design Workflow Using Machine Learning and Molecular Dynamics.</ArticleTitle><Pagination><StartPage>7626</StartPage><EndPage>7638</EndPage><MedlinePgn>7626-7638</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jcim.4c01023</ELocationID><Abstract><AbstractText><i>In silico</i> optimization of protein binding has received a great deal of attention in the recent years. Since <i>in silico</i> prefiltering of strong binders is fast and cheap compared to <i>in vitro</i> library screening methods, the advent of powerful hardware and advanced machine learning algorithms has made this strategy more accessible and preferred. These advances have already impacted the global response to pandemic threats. In this study, we proposed and tested a workflow for designing nanobodies targeting the SARS-CoV-2 spike protein receptor binding domain (S-RBD) using machine learning techniques complemented by molecular dynamics simulations. We evaluated the feasibility of this workflow using a test set of 3 different nanobodies and 2 different S-RBD variants, from <i>in silico</i> design and bacterial expression to binding assays of the designed nanobody mutants. We successfully designed nanobodies that were subsequently tested against both the wild-type (Wuhan type) and the delta variant S-RBD and found 2 of them to be stronger binders compared to the wild-type nanobody. We use this case study to describe both the strengths and weaknesses of this <i>in silico</i> assisted nanobody design strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fazekas</LastName><ForeName>Zsolt</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-5007-4807</Identifier><AffiliationInfo><Affiliation>Hevesy György PhD School of Chemistry, Institute of Chemistry, Eötvös Loránd University, Budapest, Pázmány Péter sétány. 1/A, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Structural Chemistry and Biology, Institute of Chemistry, Eötvös Loránd University, Pázmány Péter sétány 1/A, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy-Fazekas</LastName><ForeName>Dóra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hevesy György PhD School of Chemistry, Institute of Chemistry, Eötvös Loránd University, Budapest, Pázmány Péter sétány. 1/A, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Structural Chemistry and Biology, Institute of Chemistry, Eötvös Loránd University, Pázmány Péter sétány 1/A, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shilling-Tóth</LastName><ForeName>Boglárka Mária</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Eötvös Loránd University, Pázmány Péter sétány 1/C, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ecsédi</LastName><ForeName>Péter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Eötvös Loránd University, Pázmány Péter sétány 1/C, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stráner</LastName><ForeName>Pál</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>HUN-REN-ELTE Protein Modeling Research Group, Hungarian Research Network (HUN-REN), Institute of Chemistry, Eötvös Loránd University, Pázmány Péter sétány 1/A, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Structural Chemistry and Biology, Institute of Chemistry, Eötvös Loránd University, Pázmány Péter sétány 1/A, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyitray</LastName><ForeName>László</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4717-5994</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Eötvös Loránd University, Pázmány Péter sétány 1/C, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perczel</LastName><ForeName>András</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1252-6416</Identifier><AffiliationInfo><Affiliation>Medicinal Chemistry Research Group, HUN-REN Research Centre for Natural Sciences, Magyar Tudósok Körútja 2, H-1117 Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HUN-REN-ELTE Protein Modeling Research Group, Hungarian Research Network (HUN-REN), Institute of Chemistry, Eötvös Loránd University, Pázmány Péter sétány 1/A, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Structural Chemistry and Biology, Institute of Chemistry, Eötvös Loránd University, Pázmány Péter sétány 1/A, Budapest H-1117, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Chem Inf Model</MedlineTA><NlmUniqueID>101230060</NlmUniqueID><ISSNLinking>1549-9596</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061905">Single-Domain Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="Y">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061905" MajorTopicYN="Y">Single-Domain Antibodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057188" MajorTopicYN="N">Workflow</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The
authors
declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>14</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39356775</ArticleId><ArticleId IdType="pmc">PMC11481066</ArticleId><ArticleId IdType="doi">10.1021/acs.jcim.4c01023</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clinical Spectrum
of SARS-CoV-2 Infection. NIH - COVID-19 Treatment
Guidelines. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ (accessed May 22, 2024).</Citation></Reference><Reference><Citation>Shah M. M.; Patel K.; Milucky J.; Taylor C. A.; Reingold A.; Armistead I.; Meek J.; Anderson E. J.; Weigel A.; Reeg L.; Como-Sabetti K.; Ropp S. L.; Muse A.; Bushey S.; Shiltz E.; Sutton M.; Talbot H. K.; Chatelain R.; Havers F. P. the CDC COVID-NET Surveillance Team. Bacterial and Viral Infections among Adults Hospitalized with COVID-19, COVID-NET, 14 States, March 2020–April 2022. Influenza Respir. Viruses 2023, 17 (3), e1310710.1111/irv.13107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13107</ArticleId><ArticleId IdType="pmc">PMC9981874</ArticleId><ArticleId IdType="pubmed">36875205</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. COVID-19 Vaccine Product Information.
CDC - Vaccines and Immunizations. https://www.cdc.gov/vaccines/covid-19/info-by-product/ (accessed
May 22, 2024).</Citation></Reference><Reference><Citation>Therapeutic Management
of Hospitalized Adults With COVID-19. NIH
- COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/hospitalized-adults--therapeutic-management/ (accessed May 22, 2024).</Citation></Reference><Reference><Citation>Raybould M. I. J.; Kovaltsuk A.; Marks C.; Deane C. M. CoV-AbDab: The Coronavirus Antibody Database. Bioinformatics 2021, 37 (5), 734–735. 10.1093/bioinformatics/btaa739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btaa739</ArticleId><ArticleId IdType="pmc">PMC7558925</ArticleId><ArticleId IdType="pubmed">32805021</ArticleId></ArticleIdList></Reference><Reference><Citation>Leader B.; Baca Q. J.; Golan D. E. Protein Therapeutics: A Summary and Pharmacological Classification. Nat. Rev. Drug Discov 2008, 7 (1), 21–39. 10.1038/nrd2399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2399</ArticleId><ArticleId IdType="pubmed">18097458</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson R.; Edwards R. J.; Mansouri K.; Janowska K.; Stalls V.; Gobeil S. M. C.; Kopp M.; Li D.; Parks R.; Hsu A. L.; Borgnia M. J.; Haynes B. F.; Acharya P. Controlling the SARS-CoV-2 Spike Glycoprotein Conformation. Nat. Rev. Drug Discovery 2020, 27 (10), 925–933. 10.1038/s41594-020-0479-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-0479-4</ArticleId><ArticleId IdType="pmc">PMC8581954</ArticleId><ArticleId IdType="pubmed">32699321</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y.; Zhang J.; Xiao T.; Peng H.; Sterling S. M.; Walsh R. M.; Rawson S.; Rits-Volloch S.; Chen B. Distinct Conformational States of SARS-CoV-2 Spike Protein. Science 2020, 369 (6511), 1586–1592. 10.1126/science.abd4251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4251</ArticleId><ArticleId IdType="pmc">PMC7464562</ArticleId><ArticleId IdType="pubmed">32694201</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J.; Le Bas A.; Ruza R. R.; Duyvesteyn H. M. E.; Mikolajek H.; Malinauskas T.; Tan T. K.; Rijal P.; Dumoux M.; Ward P. N.; Ren J.; Zhou D.; Harrison P. J.; Weckener M.; Clare D. K.; Vogirala V. K.; Radecke J.; Moynié L.; Zhao Y.; Gilbert-Jaramillo J.; Knight M. L.; Tree J. A.; Buttigieg K. R.; Coombes N.; Elmore M. J.; Carroll M. W.; Carrique L.; Shah P. N. M.; James W.; Townsend A. R.; Stuart D. I.; Owens R. J.; Naismith J. H. Neutralizing Nanobodies Bind SARS-CoV-2 Spike RBD and Block Interaction with ACE2. Nat. Struct. Mol. Biol. 2020, 27 (9), 846–854. 10.1038/s41594-020-0469-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-0469-6</ArticleId><ArticleId IdType="pubmed">32661423</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T.; Cai H.; Yao H.; Zhou B.; Zhang N.; Van Vlissingen M. F.; Kuiken T.; Han W.; GeurtsvanKessel C. H.; Gong Y.; Zhao Y.; Shen Q.; Qin W.; Tian X.-X.; Peng C.; Lai Y.; Wang Y.; Hutter C. A. J.; Kuo S.-M.; Bao J.; Liu C.; Wang Y.; Richard A. S.; Raoul H.; Lan J.; Seeger M. A.; Cong Y.; Rockx B.; Wong G.; Bi Y.; Lavillette D.; Li D. A Synthetic Nanobody Targeting RBD Protects Hamsters from SARS-CoV-2 Infection. Nat. Commun. 2021, 12 (1), 463510.1038/s41467-021-24905-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24905-z</ArticleId><ArticleId IdType="pmc">PMC8324831</ArticleId><ArticleId IdType="pubmed">34330908</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Y.; Nambulli S.; Xiao Z.; Liu H.; Sang Z.; Duprex W. P.; Schneidman-Duhovny D.; Zhang C.; Shi Y. Versatile and Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2. Science 2020, 370 (6523), 1479–1484. 10.1126/science.abe4747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe4747</ArticleId><ArticleId IdType="pmc">PMC7857400</ArticleId><ArticleId IdType="pubmed">33154108</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoof M.; Faust B.; Saunders R. A.; Sangwan S.; Rezelj V.; Hoppe N.; Boone M.; Billesbølle C. B.; Puchades C.; Azumaya C. M.; Kratochvil H. T.; Zimanyi M.; Deshpande I.; Liang J.; Dickinson S.; Nguyen H. C.; Chio C. M.; Merz G. E.; Thompson M. C.; Diwanji D.; Schaefer K.; Anand A. A.; Dobzinski N.; Zha B. S.; Simoneau C. R.; Leon K.; White K. M.; Chio U. S.; Gupta M.; Jin M.; Li F.; Liu Y.; Zhang K.; Bulkley D.; Sun M.; Smith A. M.; Rizo A. N.; Moss F.; Brilot A. F.; Pourmal S.; Trenker R.; Pospiech T.; Gupta S.; Barsi-Rhyne B.; Belyy V.; Barile-Hill A. W.; Nock S.; Liu Y.; Krogan N. J.; Ralston C. Y.; Swaney D. L.; García-Sastre A.; Ott M.; Vignuzzi M.; Walter P.; Manglik A.; Azumaya C. M.; Puchades C.; Sun M.; Braxton J. R.; Brilot A. F.; Gupta M.; Li F.; Lopez K. E.; Melo A.; Merz G. E.; Moss F.; Paulino J.; Pospiech T. H.; Pourmal S.; Rizo A. N.; Smith A. M.; Thomas P. V.; Wang F.; Yu Z.; Dickinson M. S.; Nguyen H. C.; Asarnow D.; Campbell M. G.; Chio C. M.; Chio U. S.; Diwanji D.; Faust B.; Gupta M.; Hoppe N.; Jin M.; Li J.; Liu Y.; Merz G. E.; Sangwan S.; Tsui T. K. M.; Trenker R.; Trinidad D.; Tse E.; Zhang K.; Zhou F.; Herrera N.; Kratochvil H. T.; Schulze-Gahmen U.; Thompson M. C.; Young I. D.; Biel J.; Deshpande I.; Liu X.; Billesbølle C. B.; Nowotny C.; Smith A. M.; Zhao J.; Bowen A.; Hoppe N.; Li Y.-L.; Nguyen P.; Safari M.; Schaefer K.; Whitis N.; Moritz M.; Owens T. W.; Diallo A.; Kim K.; Peters J. K.; Titus E. W.; Chen J.; Doan L.; Flores S.; Lam V. L.; Li Y.; Lo M.; Thwin A. C.; Wankowicz S.; Zhang Y.; Bulkley D.; Joves A.; Joves A.; McKay L.; Tabios M.; Rosenberg O. S.; Verba K. A.; Agard D. A.; Cheng Y.; Fraser J. S.; Frost A.; Jura N.; Kortemme T.; Krogan N. J.; Manglik A.; Southworth D. R.; Stroud R. M. An Ultrapotent Synthetic Nanobody Neutralizes SARS-CoV-2 by Stabilizing Inactive Spike. Science 2020, 370 (6523), 1473–1479. 10.1126/science.abe3255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe3255</ArticleId><ArticleId IdType="pmc">PMC7857409</ArticleId><ArticleId IdType="pubmed">33154106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X.; Mannar D.; Srivastava S. S.; Berezuk A. M.; Demers J.-P.; Saville J. W.; Leopold K.; Li W.; Dimitrov D. S.; Tuttle K. S.; Zhou S.; Chittori S.; Subramaniam S. Cryo-Electron Microscopy Structures of the N501Y SARS-CoV-2 Spike Protein in Complex with ACE2 and 2 Potent Neutralizing Antibodies. PLoS Biol. 2021, 19 (4), e300123710.1371/journal.pbio.3001237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001237</ArticleId><ArticleId IdType="pmc">PMC8112707</ArticleId><ArticleId IdType="pubmed">33914735</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulea T.; Baardsnes J.; Stuible M.; Rohani N.; Tran A.; Parat M.; Cepero Donates Y.; Duchesne M.; Plante P.; Kour G.; Durocher Y. Structure-Based Dual Affinity Optimization of a SARS-CoV-1/2 Cross-Reactive Single-Domain Antibody. PLoS One 2022, 17 (3), e026625010.1371/journal.pone.0266250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266250</ArticleId><ArticleId IdType="pmc">PMC8967028</ArticleId><ArticleId IdType="pubmed">35353868</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy-Fazekas D.; Stráner P.; Ecsédi P.; Taricska N.; Borbély A.; Nyitray L.; Perczel A. A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System. Bioengineering 2023, 10 (3), 389.10.3390/bioengineering10030389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bioengineering10030389</ArticleId><ArticleId IdType="pmc">PMC10045489</ArticleId><ArticleId IdType="pubmed">36978780</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng C.; Vangone A.; Folkers G. E.; Xue L. C.; Bonvin A. M. J. J. iSEE: Interface Structure, Evolution, and Energy-based Machine Learning Predictor of Binding Affinity Changes upon Mutations. Proteins 2019, 87 (2), 110–119. 10.1002/prot.25630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.25630</ArticleId><ArticleId IdType="pmc">PMC6587874</ArticleId><ArticleId IdType="pubmed">30417935</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues C. H. M.; Myung Y.; Pires D. E. V.; Ascher D. B. mCSM-PPI2: Predicting the Effects of Mutations on Protein–Protein Interactions. Nucleic Acids Res. 2019, 47 (W1), W338–W344. 10.1093/nar/gkz383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz383</ArticleId><ArticleId IdType="pmc">PMC6602427</ArticleId><ArticleId IdType="pubmed">31114883</ArticleId></ArticleIdList></Reference><Reference><Citation>Myung Y.; Rodrigues C. H. M.; Ascher D. B.; Pires D. E. V. mCSM-AB2: Guiding Rational Antibody Design Using Graph-Based Signatures. Bioinformatics 2020, 36 (5), 1453–1459. 10.1093/bioinformatics/btz779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz779</ArticleId><ArticleId IdType="pubmed">31665262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M.; Cang Z.; Wei G.-W. A Topology-Based Network Tree for the Prediction of Protein–Protein Binding Affinity Changes Following Mutation. Nat. Mach. Intell. 2020, 2 (2), 116–123. 10.1038/s42256-020-0149-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42256-020-0149-6</ArticleId><ArticleId IdType="pmc">PMC7223817</ArticleId><ArticleId IdType="pubmed">34170981</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N.; Chen Y.; Lu H.; Zhao F.; Alvarez R. V.; Goncearenco A.; Panchenko A. R.; Li M. MutaBind2: Predicting the Impacts of Single and Multiple Mutations on Protein-Protein Interactions. iScience 2020, 23 (3), 10093910.1016/j.isci.2020.100939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.100939</ArticleId><ArticleId IdType="pmc">PMC7068639</ArticleId><ArticleId IdType="pubmed">32169820</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahari S.; Li G.; Murthy A. K.; Liang S.; Fragoza R.; Yu H.; Alexov E. SAAMBE-3D: Predicting Effect of Mutations on Protein–Protein Interactions. IJMS 2020, 21 (7), 2563.10.3390/ijms21072563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21072563</ArticleId><ArticleId IdType="pmc">PMC7177817</ArticleId><ArticleId IdType="pubmed">32272725</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X.; Luo Y.; Li P.; Song S.; Peng J. Deep Geometric Representations for Modeling Effects of Mutations on Protein-Protein Binding Affinity. PLoS Comput. Biol. 2021, 17 (8), e100928410.1371/journal.pcbi.1009284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1009284</ArticleId><ArticleId IdType="pmc">PMC8366979</ArticleId><ArticleId IdType="pubmed">34347784</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z.; Yamaguchi R. Machine Learning Methods for Protein-Protein Binding Affinity Prediction in Protein Design. Front. Bioinform. 2022, 2, 106570310.3389/fbinf.2022.1065703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbinf.2022.1065703</ArticleId><ArticleId IdType="pmc">PMC9800603</ArticleId><ArticleId IdType="pubmed">36591334</ArticleId></ArticleIdList></Reference><Reference><Citation>Genheden S.; Ryde U. The MM/PBSA and MM/GBSA Methods to Estimate Ligand-Binding Affinities. Expert Opin. Drug Discovery 2015, 10 (5), 449–461. 10.1517/17460441.2015.1032936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17460441.2015.1032936</ArticleId><ArticleId IdType="pmc">PMC4487606</ArticleId><ArticleId IdType="pubmed">25835573</ArticleId></ArticleIdList></Reference><Reference><Citation>The PyMOL Molecular Graphics System, Version 1.8, Schrödinger, LLC.</Citation></Reference><Reference><Citation>Schymkowitz J.; Borg J.; Stricher F.; Nys R.; Rousseau F.; Serrano L. The FoldX Web Server: An Online Force Field. Nucleic Acids Res. 2005, 33 (Web Server), W382–W388. 10.1093/nar/gki387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki387</ArticleId><ArticleId IdType="pmc">PMC1160148</ArticleId><ArticleId IdType="pubmed">15980494</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham M.; Alekseenko A.; Bergh C.; Blau C.; Briand E.; Doijade M.; Fleischmann S.; Gapsys V.; Garg G.; Gorelov S.; Gouaillardet G.; Gray A.; Irrgang M. E.; Jalalypour F.; Jordan J.; Junghans C.; K P.; Keller S.; Kutzner C.; Lemkul J. A.; Lundborg M.; Merz P.; Miletić V.; Morozov D.; Páll S.; Schulz R.; Shirts M.; Shvetsov A.; Soproni B.; Van Der Spoel D.; Turner P.; Uphoff C.; Villa A.; Wingbermühle S.; Zhmurov A.; Bauer P.; Hess B.; Lindahl E.. GROMACS 2023.2 Manual, 202310.5281/ZENODO.8134388.</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/ZENODO.8134388</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford
University - Coronavirus Antiviral &amp; Resistance Database. https://covdb.stanford.edu/page/mutation-viewer/ (accessed May 22, 2024).</Citation></Reference><Reference><Citation>Riahi S.; Lee J. H.; Wei S.; Cost R.; Masiero A.; Prades C.; Olfati-Saber R.; Wendt M.; Park A.; Qiu Y.; Zhou Y. Application of an Integrated Computational Antibody Engineering Platform to Design SARS-CoV-2 Neutralizers. Antibody Ther. 2021, 4 (3), 109–122. 10.1093/abt/tbab011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abt/tbab011</ArticleId><ArticleId IdType="pmc">PMC8344454</ArticleId><ArticleId IdType="pubmed">34396040</ArticleId></ArticleIdList></Reference><Reference><Citation>Abascal J. L. F.; Vega C. A General Purpose Model for the Condensed Phases of Water: TIP4P/2005. J. Chem. Phys. 2005, 123 (23), 23450510.1063/1.2121687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.2121687</ArticleId><ArticleId IdType="pubmed">16392929</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev A. E.; Kulke M.; Khaneja H. S.; Chudasama V.; Sheppard T. D.; Lanigan R. M. Motional Timescale Predictions by Molecular Dynamics Simulations: Case Study Using Proline and Hydroxyproline Sidechain Dynamics: Proline Force Field Parameters. Proteins 2014, 82 (2), 195–215. 10.1002/prot.24350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.24350</ArticleId><ArticleId IdType="pmc">PMC4282583</ArticleId><ArticleId IdType="pubmed">23818175</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdés-Tresanco M. S.; Valdés-Tresanco M. E.; Valiente P. A.; Moreno E. gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. J. Chem. Theory Comput. 2021, 17 (10), 6281–6291. 10.1021/acs.jctc.1c00645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.1c00645</ArticleId><ArticleId IdType="pubmed">34586825</ArticleId></ArticleIdList></Reference><Reference><Citation>Onufriev A.; Bashford D.; Case D. A. Exploring Protein Native States and Large-scale Conformational Changes with a Modified Generalized Born Model. Proteins 2004, 55 (2), 383–394. 10.1002/prot.20033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.20033</ArticleId><ArticleId IdType="pubmed">15048829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter J. D. Matplotlib: A 2D Graphics Environment. Comput. Sci. Eng. 2007, 9 (3), 90–95. 10.1109/MCSE.2007.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/MCSE.2007.55</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy-Fazekas D.; Fazekas Z.; Taricska N.; Stráner P.; Karancsiné Menyhárd D.; Perczel A. Inhibitor Design Strategy for Myostatin: Dynamics and Interaction Networks Define the Affinity and Release Mechanisms of the Inhibited Complexes. Molecules 2023, 28 (15), 5655.10.3390/molecules28155655.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28155655</ArticleId><ArticleId IdType="pmc">PMC10420283</ArticleId><ArticleId IdType="pubmed">37570625</ArticleId></ArticleIdList></Reference><Reference><Citation>Clementel D.; Del Conte A.; Monzon A. M.; Camagni G. F.; Minervini G.; Piovesan D.; Tosatto S. C. E. RING 3.0: Fast Generation of Probabilistic Residue Interaction Networks from Structural Ensembles. Nucleic Acids Res. 2022, 50 (W1), W651–W656. 10.1093/nar/gkac365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac365</ArticleId><ArticleId IdType="pmc">PMC9252747</ArticleId><ArticleId IdType="pubmed">35554554</ArticleId></ArticleIdList></Reference><Reference><Citation>Talavera D.; Robertson D. L.; Lovell S. C. Characterization of Protein-Protein Interaction Interfaces from a Single Species. PLoS One 2011, 6 (6), e2105310.1371/journal.pone.0021053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021053</ArticleId><ArticleId IdType="pmc">PMC3124478</ArticleId><ArticleId IdType="pubmed">21738603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekberg V.; Ryde U. On the Use of Interaction Entropy and Related Methods to Estimate Binding Entropies. J. Chem. Theory Comput. 2021, 17 (8), 5379–5391. 10.1021/acs.jctc.1c00374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.1c00374</ArticleId><ArticleId IdType="pmc">PMC8389774</ArticleId><ArticleId IdType="pubmed">34254810</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>